Uncategorized

Alnylam, Inceptive ink AI deal potentially worth $2B

Published

on

The RNA-focused drugmaker says Inceptive’s tools will help prioritize the best development options as well as speed up the research process.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version